Research across Metabolic Dysfunction-Associated Steatohepatitis
Related studies from across the Metabolic Dysfunction-Associated Steatohepatitis family.
Phase 2 Trial Evaluating Zalfermin and Semaglutide Combinations for Metabolic Dysfunction Associated Steatohepatitis
Trial Shows Semaglutide May Impact Liver Fibrosis in MASLD
A 52-week trial assessed whether zalfermin combined with semaglutide improves liver fibrosis in patients with advanced steatohepatitis.
A new trial suggests semaglutide may improve liver fibrosis in patients with MASLD, while other combinations did not show significant result…
rs2896019 G allele associated with 51% increased risk of MASLD susceptibility
Genetic variant linked to increased risk of fatty liver disease
This meta-analysis of 15028 adults identified the rs2896019 polymorphism (G allele) as a significant risk factor for MASLD. The study found …
A specific genetic marker may significantly increase the risk of developing and progressing to severe fatty liver disease.
AI, machine learning, and deep learning models facilitate multimodal diagnosis and prognosis in MASLD
Artificial intelligence helps identify and predict fatty liver disease
This scoping review synthesizes 73 studies regarding the role of AI, machine learning, and deep learning in diagnosing and predicting outcom…
New technology is helping doctors identify fatty liver disease and predict its progress by analyzing complex data and medical images.
MicroRNAs influence lipid metabolism, inflammation, and fibrosis in nonalcoholic steatohepatitis progression
Small molecules called microRNAs may help track and treat liver disease
This systematic review examines the role of microRNAs (miRNAs) in the pathophysiology of nonalcoholic fatty liver disease. The authors synth…
New research highlights how tiny molecules called microRNAs influence liver inflammation and scarring, offering hope for better diagnosis an…
Semaglutide improves MASH resolution (OR 3.48) and liver fat reduction in MASLD patients
Semaglutide helps resolve liver inflammation in patients with MASH
This meta-analysis of 1908 patients with MASLD and MASH found that semaglutide significantly improved MASH resolution (OR 3.48) and reduced …
New data shows semaglutide can reduce liver fat and inflammation for people with fatty liver disease, though results on scarring vary.
Proposed pathway for systematic MASLD/MASH assessment in type 2 diabetes
New Pathway Proposed to Manage Liver Disease in Diabetes Patients
This narrative review proposes a structured, risk-adapted outpatient pathway for MASLD/MASH assessment in patients with type 2 diabetes, sta…
A new proposed management plan aims to help people with type 2 diabetes identify and assess liver conditions more systematically.
Subcutaneous semaglutide more than doubles the likelihood of NASH resolution without fibrosis progression
Semaglutide shows promise for treating fatty liver disease and NASH
This meta-analysis of randomized controlled trials evaluated subcutaneous semaglutide in adults with NAFLD or NASH. The analysis found signi…
A new analysis shows that semaglutide can help resolve liver inflammation and improve metabolic health in people with fatty liver disease.
Immune crosstalk between innate and adaptive compartments drives inflammatory mechanisms in MASLD and MASH progression
Immune system crosstalk drives fatty liver disease progression
This systematic review examines the role of immune system interactions in metabolic dysfunction-associated steatotic liver disease (MASLD) a…
A new review reveals that immune cells talking to each other may be what pushes fatty liver disease toward severe liver damage.
Network meta-analysis ranks FGF21 analogs and SGLT2 inhibitors highest for MASH fibrosis
New analysis shows SGLT2 inhibitors may help liver scarring improve in adults with fatty liver disease
A network meta-analysis of 34 trials found FGF21 analogs and SGLT2 inhibitors ranked highest for improving liver fibrosis in MASH, with GLP-…
A large review of trials found SGLT2 inhibitors ranked highest for reducing liver scarring. These drugs also showed good safety and balanced…
Narrative review explores immunometabolic networks in MASH and MASLD
Future treatments for fatty liver disease may use personalized networks to guide care
This narrative review discusses metabolic dysfunction-associated steatohepatitis (MASH) and steatotic liver disease (MASLD), focusing on imm…
New ideas for treating fatty liver disease focus on personalized networks and multi-target approaches to guide future drug development.
Narrative review explores macrophage reprogramming for liver fibrosis and MASH
Scientists explore new ways to reprogram liver cells to heal damaged tissue and stop scarring
This narrative review summarizes macrophage reprogramming strategies for liver fibrosis and MASH. Approaches include gene modulation, pharma…
A recent review looks at fresh methods to change how liver immune cells behave. These changes could help heal liver scarring and improve hea…
Review of triglyceride-lowering therapies for metabolic dysfunction-associated steatotic liver disease
New Hope for Fatty Liver Disease Targets Hidden Triglyceride Problem
This narrative review synthesizes evidence on triglyceride-lowering therapies for metabolic dysfunction-associated steatotic liver disease. …
• Lowering triglycerides may directly heal fatty liver damage • Helps millions with metabolic syndrome and stubborn liver fat • Most treatme…